TG Therapeutics Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is headquartered in New York City, New York, USA.
TG Therapeutics focuses on the discovery and development of novel drugs that target B-cell signaling pathways. B-cells are a type of white blood cell involved in the immune response, and dysregulation of these cells is implicated in various diseases, including certain types of cancer and autoimmune disorders.
One of TG Therapeutics' lead products is ublituximab, an investigational monoclonal antibody that targets a protein called CD20 found on the surface of B-cells. Ublituximab is being developed for the treatment of various B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Additionally, the company is exploring combinations of ublituximab with other agents to potentially improve treatment outcomes.
Another key drug in their pipeline is umbralisib, an oral inhibitor of the phosphatidylinositol-3-kinase (PI3K) delta and casein kinase CK1 epsilon enzymes. Umbralisib is being investigated for the treatment of B-cell malignancies and autoimmune disorders, such as NHL, CLL, and multiple sclerosis.
The company is committed to advancing science and bringing innovative therapies to patients with unmet medical needs. Through its research and development efforts, TG Therapeutics aims to make a positive impact on the lives of patients battling B-cell malignancies and autoimmune diseases.